Ironwood Pharmaceuticals, Inc. (IRWD)
USD 0.65
(-31.48%)
USD 0.65
(-31.48%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 441.16 Million USD | 7.82% |
| 2022 | 409.17 Million USD | -0.74% |
| 2021 | 412.23 Million USD | 6.69% |
| 2020 | 386.38 Million USD | -4.49% |
| 2019 | 404.53 Million USD | 28.88% |
| 2018 | 313.88 Million USD | 12.56% |
| 2017 | 278.87 Million USD | 2.49% |
| 2016 | 272.08 Million USD | 81.95% |
| 2015 | 149.54 Million USD | 194.07% |
| 2014 | 50.85 Million USD | 224.36% |
| 2013 | 15.67 Million USD | -89.5% |
| 2012 | 149.28 Million USD | 126.62% |
| 2011 | 65.87 Million USD | 50.19% |
| 2010 | 43.85 Million USD | 21.48% |
| 2009 | 36.1 Million USD | 62.5% |
| 2008 | 22.21 Million USD | 112.31% |
| 2007 | 10.46 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 74.36 Million USD | -36.46% |
| 2024 Q2 | 93.89 Million USD | 26.26% |
| 2023 Q3 | 113.23 Million USD | 5.71% |
| 2023 Q4 | 117.04 Million USD | 3.36% |
| 2023 Q1 | 103.77 Million USD | -2.89% |
| 2023 Q2 | 107.11 Million USD | 3.22% |
| 2023 FY | 441.16 Million USD | 7.82% |
| 2022 Q2 | 85.77 Million USD | -11.73% |
| 2022 Q3 | 108.27 Million USD | 26.22% |
| 2022 Q4 | 106.85 Million USD | -1.31% |
| 2022 FY | 409.17 Million USD | -0.74% |
| 2022 Q1 | 97.17 Million USD | -16.78% |
| 2021 Q4 | 116.77 Million USD | 25.78% |
| 2021 FY | 412.23 Million USD | 6.69% |
| 2021 Q2 | 91.86 Million USD | 25.23% |
| 2021 Q1 | 73.36 Million USD | -36.64% |
| 2021 Q3 | 92.84 Million USD | 1.06% |
| 2020 FY | 386.38 Million USD | -4.49% |
| 2020 Q3 | 81.77 Million USD | 21.41% |
| 2020 Q2 | 67.35 Million USD | -13.32% |
| 2020 Q1 | 77.7 Million USD | -32.6% |
| 2020 Q4 | 115.78 Million USD | 41.59% |
| 2019 Q1 | 67.68 Million USD | -38.03% |
| 2019 Q3 | 130.66 Million USD | 43.74% |
| 2019 Q4 | 115.28 Million USD | -11.77% |
| 2019 FY | 404.53 Million USD | 28.88% |
| 2019 Q2 | 90.9 Million USD | 34.3% |
| 2018 Q3 | 61.07 Million USD | -20.73% |
| 2018 FY | 313.88 Million USD | 12.56% |
| 2018 Q1 | 66.54 Million USD | -21.78% |
| 2018 Q2 | 77.04 Million USD | 15.77% |
| 2018 Q4 | 109.22 Million USD | 78.86% |
| 2017 Q4 | 85.08 Million USD | 5.37% |
| 2017 Q3 | 80.74 Million USD | 31.13% |
| 2017 FY | 278.87 Million USD | 2.49% |
| 2017 Q2 | 61.57 Million USD | 19.25% |
| 2017 Q1 | 51.63 Million USD | -39.67% |
| 2016 FY | 272.08 Million USD | 81.95% |
| 2016 Q4 | 85.59 Million USD | 199.48% |
| 2016 Q3 | 28.58 Million USD | 26.08% |
| 2016 Q2 | 22.66 Million USD | -33.72% |
| 2016 Q1 | 34.2 Million USD | -24.26% |
| 2015 Q4 | 45.15 Million USD | 961.52% |
| 2015 Q2 | 19.59 Million USD | -32.25% |
| 2015 Q3 | 4.25 Million USD | -78.29% |
| 2015 Q1 | 28.92 Million USD | 16.0% |
| 2015 FY | 149.54 Million USD | 194.07% |
| 2014 Q1 | 12.68 Million USD | 181.93% |
| 2014 Q3 | -8.2 Million USD | -123.06% |
| 2014 Q4 | 24.93 Million USD | 403.9% |
| 2014 FY | 50.85 Million USD | 224.36% |
| 2014 Q2 | -3.67 Million USD | -129.0% |
| 2013 FY | 15.67 Million USD | -89.5% |
| 2013 Q2 | 6.24 Million USD | 208.55% |
| 2013 Q3 | 2.91 Million USD | -53.39% |
| 2013 Q4 | 4.49 Million USD | 54.52% |
| 2013 Q1 | 2.02 Million USD | -92.22% |
| 2012 Q1 | 12.24 Million USD | -61.91% |
| 2012 FY | 149.28 Million USD | 126.62% |
| 2012 Q3 | 70.45 Million USD | 382.43% |
| 2012 Q2 | 14.6 Million USD | 19.24% |
| 2012 Q4 | 26.01 Million USD | -63.08% |
| 2011 Q2 | 11.26 Million USD | 10.01% |
| 2011 Q4 | 32.15 Million USD | 163.17% |
| 2011 FY | 65.87 Million USD | 50.19% |
| 2011 Q3 | 12.21 Million USD | 8.49% |
| 2011 Q1 | 10.23 Million USD | -38.96% |
| 2010 Q4 | 16.77 Million USD | 85.14% |
| 2010 FY | 43.85 Million USD | 21.48% |
| 2010 Q2 | 10.95 Million USD | 21.07% |
| 2010 Q1 | 9.05 Million USD | 5.21% |
| 2010 Q3 | 9.05 Million USD | -17.34% |
| 2009 FY | 36.1 Million USD | 62.5% |
| 2009 Q1 | 5.23 Million USD | 5.17% |
| 2009 Q2 | 6.61 Million USD | 26.36% |
| 2009 Q3 | 15.25 Million USD | 130.82% |
| 2009 Q4 | 8.6 Million USD | -43.61% |
| 2008 Q4 | 4.97 Million USD | 0.0% |
| 2008 FY | 22.21 Million USD | 112.31% |
| 2007 FY | 10.46 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | -35.255% |
| Embecta Corp. | 749.9 Million USD | 41.171% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | -44.499% |
| Dynavax Technologies Corporation | 182.11 Million USD | -142.24% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -503.775% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 10.024% |
| PainReform Ltd. | -15 Thousand USD | 2941166.667% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -1382.791% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -5190.214% |
| SCYNEXIS, Inc. | 124.51 Million USD | -254.297% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -79535.938% |
| Cosmos Health Inc. | 4.34 Million USD | -10042.614% |
| Journey Medical Corporation | 52.52 Million USD | -739.969% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -5190.214% |
| Safety Shot Inc | -74.45 Thousand USD | 592603.055% |
| Alpha Teknova, Inc. | 10.29 Million USD | -4184.771% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | -2.446% |
| Bright Green Corporation | -237.01 Thousand USD | 186230.894% |
| Procaps Group, S.A. | 239.56 Million USD | -84.147% |
| Theratechnologies Inc. | 62.12 Million USD | -610.071% |
| Harrow Health, Inc. | 90.55 Million USD | -387.184% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -9197.366% |
| Biofrontera Inc. | 16.62 Million USD | -2553.275% |
| DURECT Corporation | 6.83 Million USD | -6358.205% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 15.768% |
| Cronos Group Inc. | 6.99 Million USD | -6210.493% |
| OptiNose, Inc. | 62.35 Million USD | -607.509% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 145697.36% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -14344.499% |
| Organogenesis Holdings Inc. | 309.79 Million USD | -42.406% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -8077.933% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -1217.45% |
| Radius Health, Inc. | 307.71 Million USD | -43.368% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -4277.508% |
| ProPhase Labs, Inc. | 16.23 Million USD | -2616.67% |
| Phibro Animal Health Corporation | 312.48 Million USD | -41.177% |
| Procaps Group S.A. | 239.56 Million USD | -84.147% |
| Alvotech | -69.42 Million USD | 735.476% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -33783.257% |
| Viatris Inc. | 6.43 Billion USD | 93.148% |
| Rockwell Medical, Inc. | 8.7 Million USD | -4968.474% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -708.193% |
| SIGA Technologies, Inc. | 122.09 Million USD | -261.334% |
| Tilray Brands, Inc. | 223.35 Million USD | -97.519% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -954.146% |
| Shineco, Inc. | 882.16 Thousand USD | -49908.615% |
| PetIQ, Inc. | 252.74 Million USD | -74.551% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 59269.407% |
| Incannex Healthcare Limited | 12 Thousand USD | -3676233.333% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 76.12% |
| Alimera Sciences, Inc. | 61.17 Million USD | -621.203% |
| Silver Spike Investment Corp. | 8.1 Million USD | -5344.673% |
| Assertio Holdings, Inc. | 125.04 Million USD | -252.79% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 6477269.285% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -10425.944% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -6629.103% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 18404.057% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -1526.876% |
| Hempacco Co., Inc. | -1.21 Million USD | 36384.588% |
| Talphera, Inc. | -4.89 Million USD | 9112.462% |
| Alvotech | -69.42 Million USD | 735.476% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | -99.013% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 37.825% |
| Currenc Group, Inc. | 17.35 Million USD | -2441.785% |
| Kamada Ltd. | 52.59 Million USD | -738.823% |
| Indivior PLC | 907 Million USD | 51.361% |
| Evoke Pharma, Inc. | 4.97 Million USD | -8760.857% |
| Flora Growth Corp. | 17.73 Million USD | -2387.09% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 18404.057% |
| Evolus, Inc. | 140.52 Million USD | -213.935% |
| HUTCHMED (China) Limited | 453.55 Million USD | 2.732% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | -28.256% |
| Akanda Corp. | 111.44 Thousand USD | -395740.25% |